

# Geoff McCaughan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3105513/publications.pdf>

Version: 2024-02-01

484  
papers

23,122  
citations

7096

78  
h-index

12946

131  
g-index

496  
all docs

496  
docs citations

496  
times ranked

20027  
citing authors

#	ARTICLE	IF	CITATIONS
1	Periacinar stellate shaped cells in rat pancreas: identification, isolation, and culture. <i>Gut</i> , 1998, 43, 128-133.	12.1	812
2	Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression. <i>Gastroenterology</i> , 2003, 125, 1695-1704.	1.3	681
3	Pancreatic stellate cells are activated by proinflammatory cytokines: implications for pancreatic fibrogenesis. <i>Gut</i> , 1999, 44, 534-541.	12.1	528
4	Hepascore: An Accurate Validated Predictor of Liver Fibrosis in Chronic Hepatitis C Infection. <i>Clinical Chemistry</i> , 2005, 51, 1867-1873.	3.2	482
5	A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. <i>Liver International</i> , 2011, 31, 61-80.	3.9	481
6	Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 685-697.	9.1	402
7	Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. <i>Hepatology</i> , 1996, 24, 759-765.	7.3	394
8	Activation of Pancreatic Stellate Cells in Human and Experimental Pancreatic Fibrosis. <i>American Journal of Pathology</i> , 1999, 155, 1087-1095.	3.8	382
9	CD26: A Multifunctional Integral Membrane and Secreted Protein of Activated Lymphocytes. <i>Scandinavian Journal of Immunology</i> , 2001, 54, 249-264.	2.7	326
10	Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. <i>Liver International</i> , 2005, 25, 472-489.	3.9	313
11	Fibroblast activation protein: A cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis. <i>Hepatology</i> , 1999, 29, 1768-1778.	7.3	264
12	Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) for measurement of cytokine and growth factor mRNA expression with fluorogenic probes or SYBR Green I. <i>Immunology and Cell Biology</i> , 2001, 79, 213-221.	2.3	261
13	Lamivudine Plus Low-Dose Hepatitis B Immunoglobulin to Prevent Recurrent Hepatitis B Following Liver Transplantation. <i>Gastroenterology</i> , 2007, 132, 931-937.	1.3	261
14	T lymphocytes interact with hepatocytes through fenestrations in murine liver sinusoidal endothelial cells. <i>Hepatology</i> , 2006, 44, 1182-1190.	7.3	252
15	The site of primary T cell activation is a determinant of the balance between intrahepatic tolerance and immunity. <i>Journal of Clinical Investigation</i> , 2004, 114, 701-712.	8.2	247
16	Does alcohol directly stimulate pancreatic fibrogenesis? Studies with rat pancreatic stellate cells. <i>Gastroenterology</i> , 2000, 118, 780-794.	1.3	240
17	Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. <i>FEBS Journal</i> , 2000, 267, 6140-6150.	0.2	234
18	Combination Low-Dose Hepatitis B Immune Globulin and Lamivudine Therapy Provides Effective Prophylaxis Against Posttransplantation Hepatitis B. <i>Liver Transplantation</i> , 2000, 6, 429-433.	2.4	228

#	ARTICLE	IF	CITATIONS
19	Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma. <i>Nature Communications</i> , 2021, 12, 187.	12.8	209
20	Antigen-Specific Primary Activation of CD8+ T Cells Within the Liver. <i>Journal of Immunology</i> , 2001, 166, 5430-5438.	0.8	192
21	Bone loss after liver transplantation. <i>Hepatology</i> , 1991, 14, 613-619.	7.3	182
22	Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. <i>Hepatology</i> , 2004, 39, 1239-1247.	7.3	175
23	Insights into the Pathobiology of Hepatitis C Virus-Associated Cirrhosis. <i>American Journal of Pathology</i> , 2002, 160, 641-654.	3.8	172
24	A Liver Capsular Network of Monocyte-Derived Macrophages Restricts Hepatic Dissemination of Intra-peritoneal Bacteria by Neutrophil Recruitment. <i>Immunity</i> , 2017, 47, 374-388.e6.	14.3	171
25	Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl) Tj ETQq1 1 0.784314 rgBT /Overlock 169	2.4	169
26	Increases in intrahepatic CD68 positive cells, MAC387 positive cells, and proinflammatory cytokines (particularly interleukin 18) in chronic hepatitis C infection. <i>Gut</i> , 2000, 46, 260-269.	12.1	161
27	DELETION OF SPONTANEOUS RAT LIVER ALLOGRAFT ACCEPTANCE BY DONOR IRRADIATION. <i>Transplantation</i> , 1995, 60, 233-236.	1.0	160
28	Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line. <i>Hepatology</i> , 2005, 42, 935-945.	7.3	159
29	Effective Treatment of Injecting Drug Users With Recently Acquired Hepatitis C Virus Infection. <i>Gastroenterology</i> , 2010, 138, 123-135.e2.	1.3	157
30	Animal and translational models of SARS-CoV-2 infection and COVID-19. <i>Mucosal Immunology</i> , 2020, 13, 877-891.	6.0	155
31	APASL consensus statements and management algorithms for hepatitis C virus infection. <i>Hepatology International</i> , 2012, 6, 409-435.	4.2	152
32	A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. <i>Hepatology</i> , 2008, 48, 1460-1466.	7.3	149
33	The dipeptidyl peptidase IV family in cancer and cell biology. <i>FEBS Journal</i> , 2010, 277, 1126-1144.	4.7	149
34	Zoledronic Acid Prevents Bone Loss after Liver Transplantation. <i>Annals of Internal Medicine</i> , 2006, 144, 239.	3.9	144
35	Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 615-633.	2.8	144
36	The Liver: A Special Case in Transplantation Tolerance. <i>Seminars in Liver Disease</i> , 2007, 27, 194-213.	3.6	143

#	ARTICLE	IF	CITATIONS
37	Hepatocyte entry leads to degradation of autoreactive CD8 T cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 16735-16740.	7.1	137
38	Identification of novel molecules and pathogenic pathways in primary biliary cirrhosis: cDNA array analysis of intrahepatic differential gene expression. Gut, 2001, 49, 565-576.	12.1	135
39	The role of sphingosine kinase 1 in cancer: Oncogene or non-oncogene addiction?. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2008, 1781, 442-447.	2.4	135
40	Alcoholic Liver Disease in Asia, Europe, and North America. Gastroenterology, 2016, 150, 1786-1797.	1.3	133
41	TOLERANCE TO RAT LIVER ALLOGRAFTS. Transplantation, 1996, 62, 1725-1730.	1.0	132
42	The site of primary T cell activation is a determinant of the balance between intrahepatic tolerance and immunity. Journal of Clinical Investigation, 2004, 114, 701-712.	8.2	132
43	Hepatitis C virus drug resistance and immune-driven adaptations: Relevance to new antiviral therapy. Hepatology, 2009, 49, 1069-1082.	7.3	131
44	Role of primary intrahepatic T cell activation in the "liver tolerance effect". Immunology and Cell Biology, 2002, 80, 84-92.	2.3	130
45	Feasibility of conducting a randomized control trial for liver cancer screening: Is a randomized controlled trial for liver cancer screening feasible or still needed?. Hepatology, 2011, 54, 1998-2004.	7.3	125
46	COVID-19 and comorbidities: A role for dipeptidyl peptidase 4 (DPP4) in disease severity?. Journal of Diabetes, 2020, 12, 649-658.	1.8	124
47	Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology, 2007, 46, 66-73.	7.3	122
48	Intrahepatic hepatitis C RNA levels do not correlate with degree of liver injury in patients with chronic hepatitis C. Hepatology, 1996, 23, 676-687.	7.3	121
49	Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPIP-like peptidase activity. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2004, 1679, 18-28.	2.4	116
50	Intrahepatic Murine CD8 T-Cell Activation Associates With a Distinct Phenotype Leading to Bim-Dependent Death. Gastroenterology, 2008, 135, 989-997.	1.3	114
51	PREDICTORS OF RELAPSE TO HARMFUL ALCOHOL AFTER ORTHOTOPIC LIVER TRANSPLANTATION. Alcohol and Alcoholism, 2006, 41, 278-283.	1.6	113
52	Intrahepatic expression of the hepatic stellate cell marker fibroblast activation protein correlates with the degree of fibrosis in hepatitis C virus infection. Liver, 2002, 22, 93-101.	0.1	111
53	Lamivudine therapy in patients undergoing liver transplantation for hepatitis b virus precore mutant-associated infection: High resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immu. Liver Transplantation, 1999, 5, 512-519.	1.8	110
54	Transmission of hepatitis C virus to infants of human immunodeficiency virus-negative intravenous drug-using mothers: rate of infection and assessment of risk factors for transmission. Journal of Viral Hepatitis, 1997, 4, 395-409.	2.0	109

#	ARTICLE	IF	CITATIONS
55	Two highly conserved glutamic acid residues in the predicted $\hat{I}^2$ propeller domain of dipeptidyl peptidase IV are required for its enzyme activity. <i>FEBS Letters</i> , 1999, 458, 278-284.	2.8	108
56	Patient and graft survival after liver transplantation for hereditary hemochromatosis: Implications for pathogenesis. <i>Hepatology</i> , 2004, 39, 1655-1662.	7.3	108
57	Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. <i>Journal of Viral Hepatitis</i> , 2017, 24, 823-831.	2.0	107
58	Intrahepatic immunity: a tale of two sites?. <i>Trends in Immunology</i> , 2005, 26, 512-517.	6.8	104
59	Liver fibrosis: a balance of ACEs?. <i>Clinical Science</i> , 2007, 113, 109-118.	4.3	103
60	Increased intrahepatic messenger RNA expression of interleukins 2, 6, and 8 in human cirrhosis. <i>Gastroenterology</i> , 1994, 107, 789-798.	1.3	102
61	Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: A multinational, prospective, controlled, randomized trial. <i>Liver Transplantation</i> , 2018, 24, 380-393.	2.4	101
62	Cholestatic hepatitis after liver transplantation is associated with persistently high serum hepatitis C virus RNA levels. <i>Liver Transplantation</i> , 1998, 4, 15-21.	1.8	100
63	High-Dose/Activation-Associated Tolerance. <i>Transplantation</i> , 1997, 64, 1377-1382.	1.0	95
64	EVIDENCE THAT APOPTOSIS OF ACTIVATED T CELLS OCCURS IN SPONTANEOUS TOLERANCE OF LIVER ALLOGRAFTS AND IS BLOCKED BY MANIPULATIONS WHICH BREAK TOLERANCE1. <i>Transplantation</i> , 1999, 68, 1736-1745.	1.0	95
65	Mechanisms of HCV reinfection and allograft damage after liver transplantation. <i>Journal of Hepatology</i> , 2004, 40, 368-374.	3.7	94
66	Tolerance to rat liver allografts. III. Donor cell migration and tolerance-associated cytokine production in peripheral lymphoid tissues. <i>Journal of Immunology</i> , 1996, 156, 4925-31.	0.8	94
67	Sequential increases in the intrahepatic expression of epidermal growth factor, basic fibroblast growth factor, and transforming growth factor $\gamma$ in a bile duct ligated rat model of cirrhosis. <i>Hepatology</i> , 1997, 26, 624-633.	7.3	89
68	Quantitation of fibroblast activation protein (FAP)-specific protease activity in mouse, baboon and human fluids and organs. <i>FEBS Open Bio</i> , 2014, 4, 43-54.	2.3	89
69	The In Vivo Expression of Dipeptidyl Peptidases 8 and 9. <i>Journal of Histochemistry and Cytochemistry</i> , 2009, 57, 1025-1040.	2.5	88
70	EVIDENCE THAT PORTAL TRACT MICROVASCULAR DESTRUCTION PRECEDES BILE DUCT LOSS IN HUMAN LIVER ALLOGRAFT REJECTION. <i>Transplantation</i> , 1993, 56, 69-74.	1.0	87
71	Fibrosis progression in chronic hepatitis C virus infection. <i>Gut</i> , 2004, 53, 318-321.	12.1	84
72	EARLY UP-REGULATION OF MACROPHAGES AND MYOFIBROBLASTS. <i>Transplantation</i> , 2000, 69, 2658-2662.	1.0	84

#	ARTICLE	IF	CITATIONS
73	Hepatitis B virus precore mutant infection is associated with severe recurrent disease after liver transplantation. <i>Hepatology</i> , 1995, 21, 14-18.	7.3	83
74	Binding to human dipeptidyl peptidase IV by adenosine deaminase and antibodies that inhibit ligand binding involves overlapping, discontinuous sites on a predicted I <sup>2</sup> propeller domain. <i>FEBS Journal</i> , 1999, 266, 798-810.	0.2	83
75	Diabetes is a progression factor for hepatic fibrosis in a high fat fed mouse obesity model of non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2011, 55, 435-444.	3.7	83
76	Targeting the vasculature in hepatocellular carcinoma treatment: Starving versus normalizing blood supply. <i>Clinical and Translational Gastroenterology</i> , 2017, 8, e98.	2.5	83
77	Long-term survival with tumor regression in androgen-induced liver tumors. <i>Cancer</i> , 1985, 56, 2622-2626.	4.1	82
78	Hypothalamic-pituitary-testicular function in end-stage non-alcoholic liver disease before and after liver transplantation. <i>Clinical Endocrinology</i> , 1995, 43, 331-337.	2.4	82
79	Cytokine-dependent bystander hepatitis due to intrahepatic murine CD8+ T-cell activation by bone marrow-derived cells. <i>Gastroenterology</i> , 2002, 123, 1252-1264.	1.3	82
80	Comparison of De Novo Cancer Incidence in Australian Liver, Heart and Lung Transplant Recipients. <i>American Journal of Transplantation</i> , 2013, 13, 174-183.	4.7	81
81	Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates. <i>Liver Transplantation</i> , 2013, 19, 268-274.	2.4	81
82	Antigen expression level threshold tunes the fate of CD8 T cells during primary hepatic immune responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E2540-9.	7.1	81
83	A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection. <i>Liver Transplantation</i> , 2004, 10, 52-57.	2.4	79
84	Thrombocytopenia post liver transplantation. <i>Journal of Hepatology</i> , 1992, 16, 16-22.	3.7	78
85	Gene Expression Profiling of Alcoholic Liver Disease in the Baboon ( <i>Papio hamadryas</i> ) and Human Liver. <i>American Journal of Pathology</i> , 2003, 163, 2303-2317.	3.8	78
86	Molecular pathogenesis of liver disease: an approach to hepatic inflammation, cirrhosis and liver transplant tolerance. <i>Immunological Reviews</i> , 2000, 174, 172-191.	6.0	77
87	Mutations in the hepatitis B virus precore/core gene and core promoter in patients with severe recurrent disease following liver transplantation. <i>Hepatology</i> , 1996, 24, 1371-1378.	7.3	76
88	Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591986269.	3.2	75
89	Identification of the bile canalicular cell surface molecule GP110 as the ectopeptidase dipeptidyl peptidase IV: An analysis by tissue distribution, purification and N-terminal amino acid sequence. <i>Hepatology</i> , 1990, 11, 534-544.	7.3	73
90	Novel Aspects of the Liver Microenvironment in Hepatocellular Carcinoma Pathogenesis and Development. <i>International Journal of Molecular Sciences</i> , 2014, 15, 9422-9458.	4.1	73

#	ARTICLE	IF	CITATIONS
91	Clonal expansion of hepatocytes with a selective advantage occurs during all stages of chronic hepatitis B virus infection. <i>Journal of Viral Hepatitis</i> , 2015, 22, 737-753.	2.0	73
92	Frailty in advanced liver disease. <i>Liver International</i> , 2018, 38, 2117-2128.	3.9	73
93	VASCULAR ENDOTHELIAL GROWTH FACTOR EXPRESSION IN HUMAN CHRONIC RENAL ALLOGRAFT REJECTION1. <i>Transplantation</i> , 1999, 67, 929-933.	1.0	73
94	APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation. <i>Hepatology International</i> , 2019, 13, 649-661.	4.2	72
95	Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. <i>Journal of Hepatology</i> , 2013, 58, 467-472.	3.7	71
96	KINETICS OF INTRAGRAFT CYTOKINE EXPRESSION, CELLULAR INFILTRATION, AND CELL DEATH IN REJECTION OF RENAL ALLOGRAFTS COMPARED WITH ACCEPTANCE OF LIVER ALLOGRAFTS IN A RAT MODEL. <i>Transplantation</i> , 1998, 65, 1370-1377.	1.0	70
97	De novo Cancer-Related Death in Australian Liver and Cardiothoracic Transplant Recipients. <i>American Journal of Transplantation</i> , 2013, 13, 1296-1304.	4.7	69
98	Structural Requirements for Catalysis, Expression, and Dimerization in the CD26/DPIV Gene Family. <i>Biochemistry</i> , 2003, 42, 694-701.	2.5	67
99	Cytochrome P4502E1 is present in rat pancreas and is induced by chronic ethanol administration. <i>Gut</i> , 1998, 42, 426-430.	12.1	66
100	Intrahepatic cytokine profiles associated with posttransplantation hepatitis C virus-related liver injury. <i>Liver Transplantation</i> , 2002, 8, 292-301.	2.4	66
101	Extraenzymatic functions of the dipeptidyl peptidase IV-related proteins DP8 and DP9 in cell adhesion, migration and apoptosis. <i>FEBS Journal</i> , 2006, 273, 2447-2460.	4.7	66
102	Expression of the rat CD26 Antigen (dipeptidyl peptidase IV) on subpopulations of rat lymphocytes. <i>Cellular Immunology</i> , 1991, 134, 205-215.	3.0	65
103	Osteoporosis in Chronic Liver Disease: Pathogenesis, Risk Factors, and Management. <i>Digestive Diseases</i> , 1994, 12, 223-231.	1.9	65
104	Intrahepatic gene expression in human alcoholic hepatitis. <i>Journal of Hepatology</i> , 2006, 45, 306-320.	3.7	65
105	Anti-Neutrophil cytoplasmic antibody: A prognostic indicator in primary sclerosing cholangitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1994, 9, 40-44.	2.8	63
106	Evidence of continuing bone recovery at a mean of 7 years after liver transplantation. <i>Liver Transplantation</i> , 1999, 5, 407-413.	1.8	62
107	An International Comparison of the Effect of Policy Shifts to Organ Donation following Cardiac Death (DCD) on Donation Rates after Brain Death (DBD) and Transplantation Rates. <i>PLoS ONE</i> , 2013, 8, e62010.	2.5	62
108	A quantitative analysis of T lymphocyte populations in human liver allografts undergoing rejection: The use of monoclonal antibodies and double immunolabeling. <i>Hepatology</i> , 1990, 12, 1305-1313.	7.3	61

#	ARTICLE	IF	CITATIONS
109	Hypothalamic-pituitary adrenal function in end-stage non-alcoholic liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1993, 8, 247-253.	2.8	61
110	Allele non-amplification: a source of confusion in linkage studies employing microsatellite polymorphisms. <i>Human Molecular Genetics</i> , 1993, 2, 289-291.	2.9	61
111	Pathogenesis and management of alcoholic hepatitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2003, 18, 1332-1344.	2.8	61
112	SMART amplification maintains representation of relative gene expression: quantitative validation by real time PCR and application to studies of alcoholic liver disease in primates. <i>Journal of Proteomics</i> , 2003, 55, 53-66.	2.4	61
113	Fibroblast activation protein and chronic liver disease. <i>Frontiers in Bioscience - Landmark</i> , 2008, 13, 3168.	3.0	61
114	Liver transplantation for HCV-associated liver cirrhosis: Predictors of outcomes in a population with significant genotype 3 and 4 distribution. <i>Liver Transplantation</i> , 2003, 9, 339-347.	2.4	60
115	Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. <i>Hepatology</i> , 2009, 50, 1017-1029.	7.3	60
116	Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: A randomized controlled trial. <i>Hepatology</i> , 2009, 50, 1045-1055.	7.3	60
117	Regulation of vascular leak and recovery from ischemic injury by general and VE-cadherin-restricted miRNA antagonists of miR-27. <i>Blood</i> , 2013, 122, 2911-2919.	1.4	60
118	A LARGE, SINGLE CENTER INVESTIGATION OF THE IMMUNOGENETIC FACTORS AFFECTING LIVER TRANSPLANTATION. <i>Transplantation</i> , 2000, 69, 1491-1498.	1.0	59
119	A Novel Role of Dipeptidyl Peptidase 9 in Epidermal Growth Factor Signaling. <i>Molecular Cancer Research</i> , 2011, 9, 948-959.	3.4	58
120	TOLERANCE TO RAT LIVER ALLOGRAFTS. <i>Transplantation</i> , 1994, 57, 1349-1357.	1.0	57
121	A SHORT COURSE OF METHYLPREDNISOLONE IMMUNOSUPPRESSION INHIBITS BOTH REJECTION AND SPONTANEOUS ACCEPTANCE OF RAT LIVER ALLOGRAFTS. <i>Transplantation</i> , 2001, 72, 44-51.	1.0	57
122	Intra-graft cytokine mRNA levels in human liver allograft rejection analysed by reverse transcription and semiquantitative polymerase chain reaction amplification. <i>Transplant Immunology</i> , 1993, 1, 253-261.	1.2	56
123	Post-transplant quasispecies pattern remains stable over time in patients with recurrent cholestatic hepatitis due to hepatitis C virus. <i>Journal of Hepatology</i> , 2000, 32, 126-134.	3.7	56
124	The epidemiology of hepatitis C in Australia: Notifications, treatment uptake and liver transplantations, 1997-2006. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 1648-1654.	2.8	56
125	Characterization of the human homolog of the rat MRC OX-2 membrane glycoprotein. <i>Immunogenetics</i> , 1987, 25, 329-335.	2.4	55
126	Immune activation is required for the induction of liver allograft tolerance: Implications for immunosuppressive therapy. <i>Liver Transplantation</i> , 2001, 7, 161-172.	2.4	55



#	ARTICLE	IF	CITATIONS
127	Pathogenesis of hepatitis C virus recurrence in the liver allograft. <i>Liver Transplantation</i> , 2002, 8, S7-S13.	2.4	55
128	Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. <i>Hepatology</i> , 1996, 24, 759-765.	7.3	55
129	Changes in Tacrolimus Distribution in Blood and Plasma Protein Binding Following Liver Transplantation. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 506-515.	2.0	54
130	Soluble CD26 $\alpha$ / $\beta$ Dipeptidyl Peptidase IV Enhances Human Lymphocyte Proliferation <i>In Vitro</i> Independent of Dipeptidyl Peptidase Enzyme Activity and Adenosine Deaminase Binding. <i>Scandinavian Journal of Immunology</i> , 2011, 73, 102-111.	2.7	54
131	Midkine Increases Diagnostic Yield in AFP Negative and NASH-Related Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0155800.	2.5	54
132	Targeting Vascular Endothelial-Cadherin in Tumor-Associated Blood Vessels Promotes T-cell-Mediated Immunotherapy. <i>Cancer Research</i> , 2017, 77, 4434-4447.	0.9	52
133	Early intrahepatic antigen-specific retention of na $\beta$ ve CD8 $^{+}$ T cells is predominantly ICAM-1/LFA-1 dependent in mice. <i>Hepatology</i> , 2005, 42, 1063-1071.	7.3	51
134	Early high peak hepatitis C viral load levels independently predict hepatitis C-related liver failure post-liver transplantation. <i>Liver Transplantation</i> , 2009, 15, 709-718.	2.4	51
135	Altered zonal expression of the CD26 antigen (dipeptidyl peptidase IV) in human cirrhotic liver. <i>Hepatology</i> , 1992, 15, 1048-1053.	7.3	50
136	Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 563-573.	4.2	50
137	Neuronal/lymphoid membrane glycoprotein MRC OX-2 is a member of the immunoglobulin superfamily with a light-chain-like structure. <i>Biochemical Society Symposia</i> , 1986, 51, 149-57.	2.7	50
138	Novel differential gene expression in human cirrhosis detected by suppression subtractive hybridization. <i>Hepatology</i> , 2003, 38, 577-588.	7.3	48
139	Marked changes of the hepatic sinusoid in a transgenic mouse model of acute immune-mediated hepatitis. <i>Journal of Hepatology</i> , 2007, 46, 239-246.	3.7	48
140	Direct effects of alcohol on hepatic fibrinolytic balance: Implications for alcoholic liver disease. <i>Journal of Hepatology</i> , 2008, 48, 614-627.	3.7	48
141	Effects of ethanol and protein deficiency on pancreatic digestive and lysosomal enzymes. <i>Gut</i> , 1995, 36, 287-293.	12.1	46
142	Biliary strictures after liver transplantation: Clinical picture, correlates and outcomes. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1996, 11, 21-25.	2.8	46
143	Gene array analysis and the liver. <i>Hepatology</i> , 2002, 36, 1313-1325.	7.3	46
144	Spontaneous acceptance of liver transplants in rodents: Evidence that liver leucocytes induce recipient T $\alpha$ cell death by neglect. <i>Immunology and Cell Biology</i> , 2002, 80, 93-100.	2.3	46

#	ARTICLE	IF	CITATIONS
145	Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors. <i>Clinical Transplantation</i> , 2006, 20, 369-373.	1.6	46
146	Two lymph nodes draining the mouse liver are the preferential site of DC migration and T cell activation. <i>Journal of Hepatology</i> , 2012, 57, 352-358.	3.7	46
147	Detection of serum hepatitis C virus RNA in HCV antibody-seropositive volunteer blood donors. <i>Hepatology</i> , 1993, 18, 485-490.	7.3	45
148	Non-Oxidative Metabolism of Ethanol by Rat Pancreatic Acini. <i>Pancreatology</i> , 2004, 4, 82-89.	1.1	45
149	Development and resolution of experimental colitis in mice with targeted deletion of dipeptidyl peptidase IV. <i>Journal of Cellular Physiology</i> , 2005, 204, 687-692.	4.1	45
150	Immune outcomes in the liver: Is CD8 T cell fate determined by the environment?. <i>Journal of Hepatology</i> , 2015, 63, 1005-1014.	3.7	45
151	Cardiovascular mortality following liver transplantation: predictors and temporal trends over 30 years. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2020, 6, 243-253.	4.0	45
152	Circulating dipeptidyl peptidase-4 activity correlates with measures of hepatocyte apoptosis and fibrosis in non-alcoholic fatty liver disease in type 2 diabetes mellitus and obesity: A dual cohort cross-sectional study. <i>Journal of Diabetes</i> , 2015, 7, 809-819.	1.8	44
153	Osteopontin is an important mediator of alcoholic liver disease via hepatic stellate cell activation. <i>World Journal of Gastroenterology</i> , 2014, 20, 13088.	3.3	44
154	Cytokines and chemokines in the immune response to hepatitis C infection. <i>Current Opinion in Infectious Diseases</i> , 2001, 14, 279-287.	3.1	43
155	Posttransplant Administration of Donor Leukocytes Induces Long-Term Acceptance of Kidney or Liver Transplants by an Activation-Associated Immune Mechanism. <i>Journal of Immunology</i> , 2001, 166, 5258-5264.	0.8	43
156	Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing. <i>Journal of Hepatology</i> , 2010, 53, 616-623.	3.7	42
157	Hepatic artery stenosis after liver transplantation: Is endovascular treatment always necessary?. <i>Liver Transplantation</i> , 2015, 21, 162-168.	2.4	42
158	Hepatocyte Produced Matrix Metalloproteinases Are Regulated by CD147 in Liver Fibrogenesis. <i>PLoS ONE</i> , 2014, 9, e90571.	2.5	42
159	The heterogeneity of bone disease in cirrhosis: a multivariate analysis. <i>Osteoporosis International</i> , 2003, 14, 987-994.	3.1	41
160	Deletion of sphingosine kinase 1 ameliorates hepatic steatosis in diet-induced obese mice: Role of PPAR $\gamma$ . <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2016, 1861, 138-147.	2.4	41
161	Identification of Novel Natural Substrates of Fibroblast Activation Protein-alpha by Differential Degradomics and Proteomics. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 65-85.	3.8	41
162	Restoring the natural tropism of AAV2 vectors for human liver. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	41

#	ARTICLE	IF	CITATIONS
163	Dipeptidyl peptidase IV is a target for covalent adduct formation with the acyl glucuronide metabolite of the anti-inflammatory drug zomepirac. <i>Life Sciences</i> , 2001, 68, 785-797.	4.3	40
164	Impact of immunosuppression on immunopathogenesis of liver damage in hepatitis C virus-infected recipients following liver transplantation. <i>Liver Transplantation</i> , 2003, 9, S21-S27.	2.4	40
165	Vitamin D replacement for cirrhosis-related bone disease. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , 2006, 3, 689-699.	1.7	40
166	Approaching the Promise of Operational Tolerance in Clinical Transplantation. <i>Transplantation</i> , 2011, 91, 1065-1074.	1.0	40
167	Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 268-277.	4.4	39
168	Sclerosing cholangitis and biliary tract calculi—primary or secondary?. <i>Gut</i> , 1992, 33, 1376-1380.	12.1	38
169	Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1. <i>Hepatology</i> , 2011, 53, 1109-1117.	7.3	37
170	Liver transplantation in Australia and New Zealand. <i>Liver Transplantation</i> , 2016, 22, 830-838.	2.4	37
171	The gene for MRC OX-2 membrane glycoprotein is localized on human chromosome 3. <i>Immunogenetics</i> , 1987, 25, 133-135.	2.4	36
172	Increasing Incidence of Nonalcoholic Steatohepatitis as an Indication for Liver Transplantation in Australia and New Zealand. <i>Liver Transplantation</i> , 2019, 25, 25-34.	2.4	35
173	Sulfasalazine-Induced Fulminant Hepatic Failure. <i>Journal of Clinical Gastroenterology</i> , 1992, 14, 132-135.	2.2	34
174	Case Report: Delayed resolution of severe pulmonary hypertension after isolated liver transplantation in a patient with cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1996, 11, 734-737.	2.8	34
175	Experimental autoimmune cholangitis: a mouse model of immune-mediated cholangiopathy. <i>Liver International</i> , 2000, 20, 351-356.	3.9	34
176	Molecular and Cellular Aspects of Hepatitis C Virus Reinfection After Liver Transplantation: How the Early Phase Impacts on Outcomes. <i>Transplantation</i> , 2009, 87, 1105-1111.	1.0	33
177	Regulation of dipeptidyl peptidase 8 and 9 expression in activated lymphocytes and injured liver. <i>World Journal of Gastroenterology</i> , 2013, 19, 2883-2893.	3.3	33
178	Hepatitis C in injecting drug-using women during and after pregnancy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 175-181.	2.8	32
179	Discoidin Domain Receptor 1. <i>American Journal of Pathology</i> , 2011, 178, 1134-1144.	3.8	32
180	Neuropeptide Y is a physiological substrate of fibroblast activation protein: Enzyme kinetics in blood plasma and expression of Y2R and Y5R in human liver cirrhosis and hepatocellular carcinoma. <i>Peptides</i> , 2016, 75, 80-95.	2.4	32

#	ARTICLE	IF	CITATIONS
181	The pro-fibrotic role of dipeptidyl peptidase 4 in carbon tetrachloride-induced experimental liver injury. <i>Immunology and Cell Biology</i> , 2017, 95, 443-453.	2.3	32
182	Paradoxical early immune activation during acceptance of liver allografts compared with rejection of skin grafts in a rat model of transplantation. <i>Immunology</i> , 1998, 95, 257-263.	4.4	31
183	Effects of immunosuppression and organ transplantation on the natural history and immunopathogenesis of hepatitis C virus infection. <i>Transplant Infectious Disease</i> , 2000, 2, 166-185.	1.7	31
184	Inflammation and Repair in Viral Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2008, 53, 1468-1487.	2.3	31
185	Dipeptidyl peptidase 9 subcellular localization and a role in cell adhesion involving focal adhesion kinase and paxillin. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2015, 1853, 470-480.	4.1	31
186	Bone loss after liver transplantation. <i>Hepatology</i> , 1991, 14, 613-619.	7.3	31
187	Suicidal emperipolesis: a process leading to cell-in-cell structures, T cell clearance and immune homeostasis.. <i>Current Molecular Medicine</i> , 2015, 15, 819-827.	1.3	31
188	Inflammatory Pseudotumor of the Liver Causing Biliary Obstruction. <i>Journal of Clinical Gastroenterology</i> , 1991, 13, 338-341.	2.2	30
189	Tolerance in liver transplantation. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 73-84.	2.4	30
190	An association of large-fibre peripheral nerve dysfunction with non-invasive measures of liver fibrosis secondary to non-alcoholic fatty liver disease in diabetes. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 1240-1247.	2.3	30
191	Additive impact of pre-liver transplant metabolic factors on survival post-liver transplant. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1016-1024.	2.8	30
192	Supplementation with Synbiotics and/or Branched Chain Amino Acids in Hepatic Encephalopathy: A Pilot Randomised Placebo-Controlled Clinical Study. <i>Nutrients</i> , 2019, 11, 1810.	4.1	30
193	The molecular diagnosis of rejection in liver transplant biopsies: First results of the INTERLIVER study. <i>American Journal of Transplantation</i> , 2020, 20, 2156-2172.	4.7	30
194	Ethanol-induced alterations in messenger RNA levels correlate with glandular content of pancreatic enzymes. <i>Translational Research</i> , 1995, 125, 634-40.	2.3	30
195	GIANT CAVERNOUS HAEMANGIOMA: A RARE INDICATION FOR LIVER TRANSPLANTATION. <i>ANZ Journal of Surgery</i> , 1996, 66, 122-124.	0.7	29
196	Spontaneous acceptance of mouse kidney allografts is associated with increased Foxp3 expression and differences in the B and T cell compartments. <i>Transplant Immunology</i> , 2011, 24, 149-156.	1.2	29
197	Divergent Inflammatory, Fibrogenic, and Liver Progenitor Cell Dynamics in Two Common Mouse Models of Chronic Liver Injury. <i>American Journal of Pathology</i> , 2016, 186, 1762-1774.	3.8	29
198	Intrahepatic Activation of Naive CD4+ T Cells by Liver-Resident Phagocytic Cells. <i>Journal of Immunology</i> , 2014, 193, 2087-2095.	0.8	28

#	ARTICLE	IF	CITATIONS
199	Quantitative reverse transcriptase-PCR amplification of cytokine mRNA in liver biopsy specimens using a non-competitive method. <i>Immunology and Cell Biology</i> , 1997, 75, 142-147.	2.3	27
200	Donor fatty (steatotic) liver allografts in orthotopic liver transplantation. <i>Transplantation Proceedings</i> , 1998, 30, 3286-3287.	0.6	27
201	Naïve CD8 T cell activation by liver bone marrow-derived cells leads to a "neglected" IL-2low Bimhigh phenotype, poor CTL function and cell death. <i>Journal of Hepatology</i> , 2012, 57, 830-836.	3.7	27
202	Acute and subacute fulminant hepatic failure: the role of liver transplantation. <i>Medical Journal of Australia</i> , 1991, 154, 724-728.	1.7	27
203	To MELD or not to MELD?. <i>Hepatology</i> , 2001, 34, 215-215.	7.3	26
204	A Novel Purification Procedure for Active Recombinant Human DPP4 and the Inability of DPP4 to Bind SARS-CoV-2. <i>Molecules</i> , 2020, 25, 5392.	3.8	26
205	Striking variability of hepatic copper levels in fulminant hepatic failure. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1992, 7, 396-398.	2.8	25
206	Spontaneous Clearance of Hepatitis C Virus Infection Post-Liver Transplantation Is Associated With Rapidly Changing Quasispecies: A Single Case Report. <i>Liver Transplantation</i> , 2000, 6, 648-653.	2.4	25
207	The hepatic transcriptome in human liver disease. <i>Comparative Hepatology</i> , 2006, 5, 6.	0.9	25
208	Differential migration of passenger leukocytes and rapid deletion of naive alloreactive CD8 T cells after mouse liver transplantation. <i>Liver Transplantation</i> , 2013, 19, 1224-1235.	2.4	25
209	Analysis of the intrahepatic ductular reaction and progenitor cell responses in hepatitis C virus recurrence after liver transplantation. <i>Liver Transplantation</i> , 2014, 20, 1508-1519.	2.4	25
210	<i>ITPA</i> genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response. <i>Hepatology</i> , 2014, 59, 2152-2160.	7.3	25
211	Expression of growth arrest-specific gene 6 and its receptors in a rat model of chronic renal transplant rejection. <i>Transplantation</i> , 2002, 73, 657-660.	1.0	25
212	Dipeptidyl Peptidase IV Gene Family. , 2003, 524, 79-86.		24
213	Donor IL-4-treatment induces alternatively activated liver macrophages and IDO-expressing NK cells and promotes rat liver allograft acceptance. <i>Transplant Immunology</i> , 2010, 22, 172-178.	1.2	24
214	Dipeptidyl peptidase 9 enzymatic activity influences the expression of neonatal metabolic genes. <i>Experimental Cell Research</i> , 2016, 342, 72-82.	2.6	24
215	Clinical assessment and incidence of hepatitis C RNA in 50 consecutive RIBA-positive volunteer blood donors. <i>Medical Journal of Australia</i> , 1992, 157, 231-233.	1.7	24
216	Primary graft dysfunction after liver transplantation. <i>Transplantation Proceedings</i> , 2000, 32, 2219-2220.	0.6	23

#	ARTICLE	IF	CITATIONS
217	Incisional hernia following orthotopic liver transplantation. <i>Transplantation Proceedings</i> , 2003, 35, 425-426.	0.6	23
218	High azathioprine dose and lip cancer risk in liver, heart, and lung transplant recipients: A population-based cohort study. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 1144-1152.e6.	1.2	23
219	Structure and Function in Dipeptidyl Peptidase IV and Related Proteins. , 2006, 575, 45-54.		23
220	Postoperative administration of donor B cells induces rat kidney allograft acceptance: lack of association with TH2 cytokine expression in long-term accepted grafts1. <i>Transplantation</i> , 2002, 73, 1123-1130.	1.0	22
221	Molecular characterization of a novel dipeptidyl peptidase like 2-short form (DPL2-s) that is highly expressed in the brain and lacks dipeptidyl peptidase activity. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2006, 1764, 33-43.	2.3	22
222	Hereditary lysozyme amyloidosis: Spontaneous hepatic rupture (15 years apart) in mother and daughter. role of emergency liver transplantation. <i>Liver Transplantation</i> , 2006, 12, 1152-1155.	2.4	22
223	Effect of Ascites on Bone Density Measurement in Cirrhosis. <i>Journal of Clinical Densitometry</i> , 2007, 10, 391-394.	1.2	22
224	Outcome of patients with hepatocellular carcinoma referred to a tertiary centre with availability of multiple treatment options including cadaveric liver transplantation. <i>Liver International</i> , 2007, 27, 1240-1248.	3.9	22
225	Donor and recipient selection leads to good patient and graft outcomes for right lobe split transplantation versus whole graft liver transplantation in adult recipients. <i>Liver Transplantation</i> , 2009, 15, 1586-1593.	2.4	22
226	Iatrogenic immunosuppression and risk of non-Hodgkin lymphoma in solid organ transplantation: A population-based cohort study in Australia. <i>British Journal of Haematology</i> , 2016, 174, 550-562.	2.5	22
227	Epidemiology and outcomes of primary sclerosing cholangitis with and without inflammatory bowel disease in an Australian cohort. <i>Liver International</i> , 2017, 37, 442-448.	3.9	22
228	Epidemiology and Etiologic Associations of Non-alcoholic Fatty Liver Disease and Associated HCC. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1061, 3-18.	1.6	22
229	Liver transplantation for primary sclerosing cholangitis versus primary biliary cirrhosis: A comparison of complications and outcome. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1993, 8, 238-243.	2.8	21
230	A follow up of 53 adult patients alive beyond 2 years following liver transplantation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1993, 8, 569-573.	2.8	21
231	Asian perspectives on viral hepatitis: Hepatitis C virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, C90-3.	2.8	21
232	Orthotopic liver transplantation for treatment of patients with Budd-Chiari syndrome: a single-center experience. <i>Transplantation Proceedings</i> , 2000, 32, 2206-2207.	0.6	21
233	Up-regulation of proliferative genes and the ligand/receptor pair placental growth factor and vascular endothelial growth factor receptor 1 in hepatitis C cirrhosis. <i>Liver International</i> , 2007, 27, 960-968.	3.9	21
234	Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity. <i>Diabetes Research and Clinical Practice</i> , 2015, 108, 466-472.	2.8	21

#	ARTICLE	IF	CITATIONS
235	Multiple liver insults synergize to accelerate experimental hepatocellular carcinoma. <i>Scientific Reports</i> , 2018, 8, 10283.	3.3	21
236	Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1314-1322.	3.7	21
237	Differential Impact of Extended Criteria Donors After Brain Death or Circulatory Death in Adult Liver Transplantation. <i>Liver Transplantation</i> , 2020, 26, 1603-1617.	2.4	21
238	Daily determination of individual serum bile acids allows early detection of hepatic allograft dysfunction. <i>Hepatology</i> , 1994, 20, 1458-1464.	7.3	20
239	Blocking Indoleamine Dioxygenase Activity Early After Rat Liver Transplantation Prevents Long-Term Survival But Does Not Cause Acute Rejection. <i>Transplantation</i> , 2008, 85, 1357-1361.	1.0	20
240	Postreperfusion microcirculatory derangements after liver transplantation: Relationship to hemodynamics, serum mediators, and outcome. <i>Liver Transplantation</i> , 2017, 23, 527-536.	2.4	20
241	Gene array analysis and the liver. <i>Hepatology</i> , 2002, 36, 1313-1325.	7.3	20
242	Chronic ethanol administration decreases rat pancreatic GP2 content. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1997, 1336, 89-98.	2.4	19
243	The effect of ethanol on pancreatic enzymes—a dietary artefact?. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1998, 1379, 314-324.	2.4	19
244	LIVER TRANSPLANTATION IN PATIENTS WITH TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNTS. <i>ANZ Journal of Surgery</i> , 2000, 70, 493-495.	0.7	19
245	Hepatocellular carcinoma: current approaches to diagnosis and management. <i>Internal Medicine Journal</i> , 2002, 32, 394-400.	0.8	19
246	Intrahepatic Expression of Collagen and Fibroblast Activation Protein (FAP) in Hepatitis C Virus Infection. , 2003, 524, 235-243.		19
247	Overexpression of indoleamine dioxygenase in rat liver allografts using a high-efficiency adeno-associated virus vector does not prevent acute rejection. <i>Liver Transplantation</i> , 2009, 15, 233-241.	2.4	19
248	Minimal but significant improvement in survival for non-hepatitis C-related adult liver transplant patients beyond the one-year posttransplant mark. <i>Liver Transplantation</i> , 2010, 16, 130-137.	2.4	19
249	Should the liver transplant criteria for hepatocellular carcinoma be different for deceased donation and living donation?. <i>Liver Transplantation</i> , 2011, 17, S133-S138.	2.4	19
250	Gene Therapy for Tolerance. <i>Transplantation</i> , 2013, 95, 70-77.	1.0	19
251	The RhoGAP protein ARHGAP18/SENEX localizes to microtubules and regulates their stability in endothelial cells. <i>Molecular Biology of the Cell</i> , 2017, 28, 1066-1078.	2.1	19
252	Deletion of sphingosine kinase 1 inhibits liver tumorigenesis in diethylnitrosamine-treated mice. <i>Oncotarget</i> , 2018, 9, 15635-15649.	1.8	19

#	ARTICLE	IF	CITATIONS
253	The first five years' clinical experience of the Australian National Liver Transplantation Unit. Medical Journal of Australia, 1992, 156, 9-16.	1.7	18
254	ABO BLOOD GROUP INCOMPATIBILITY IN LIVER TRANSPLANTATION: A SINGLE-CENTRE EXPERIENCE. ANZ Journal of Surgery, 1997, 67, 275-278.	0.7	18
255	Post Proline Cleaving Peptidases Having DP IV Like Enzyme Activity. , 2000, 477, 103-109.		18
256	Liver biopsy: is it still relevant?. Internal Medicine Journal, 2006, 36, 689-691.	0.8	18
257	Gene array analysis of a rat model of liver transplant tolerance identifies increased complement C3 and the STAT-1/IRF-1 pathway during tolerance induction. Liver Transplantation, 2006, 12, 636-643.	2.4	18
258	Isolated liver transplantation in children with cystic fibrosis - An Australian experience. Pediatric Transplantation, 2010, 14, 779-785.	1.0	18
259	A rare variant in human fibroblast activation protein associated with ER stress, loss of enzymatic function and loss of cell surface localisation. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2014, 1844, 1248-1259.	2.3	18
260	Beyond liver fibrosis: Hepatic stellate cell senescence links obesity to liver cancer by way of the microbiome. Hepatology, 2014, 59, 2413-2415.	7.3	18
261	Sofosbuvir and daclatasvir therapy in patients with hepatitis C-related advanced decompensated liver disease (<scp>MELD</scp> >= 15). Alimentary Pharmacology and Therapeutics, 2018, 47, 401-411.	3.7	18
262	Virus Genotype-Dependent Transcriptional Alterations in Lipid Metabolism and Inflammation Pathways in the Hepatitis C Virus-infected Liver. Scientific Reports, 2019, 9, 10596.	3.3	18
263	Drug-induced liver injury in Australia, 2009-2020: the increasing proportion of non-paracetamol cases linked with herbal and dietary supplements. Medical Journal of Australia, 2021, 215, 261-268.	1.7	18
264	T cell-replacing factor in specific antibody responses to influenza virus by human blood B cells. European Journal of Immunology, 1985, 15, 52-59.	2.9	17
265	Pancreatitis in adult orthotopic liver allograft recipients: Risk factors and outcome. Liver Transplantation, 2000, 6, 362-366.	2.4	17
266	Parenchymal Expression of CD86/B7.2 Contributes to Hepatitis C Virus-Related Liver Injury. Journal of Virology, 2005, 79, 10730-10739.	3.4	17
267	Usage and outcomes of deceased donor liver allografts with preprocurement injury from blunt trauma. Liver Transplantation, 2009, 15, 321-325.	2.4	17
268	Bone marrow stem cells and the liver: Are they relevant?. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, 1608-1616.	2.8	17
269	High-dose/activation-associated tolerance model for allografts: lessons from spontaneous tolerance of transplanted livers. Current Opinion in Organ Transplantation, 1999, 4, 58.	1.6	17
270	Both ethanol and protein deficiency increase messenger RNA levels for pancreatic lithostathine. Life Sciences, 1996, 58, 485-492.	4.3	16



#	ARTICLE	IF	CITATIONS
271	Current approaches to the diagnosis and management of hepatocellular carcinoma. <i>Clinical and Experimental Medicine</i> , 2005, 5, 1-13.	3.6	16
272	Pathogenesis of cholestatic hepatitis C. <i>Journal of Hepatology</i> , 2011, 54, 392-394.	3.7	16
273	An update on the pathophysiology and management of polycystic liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 569-581.	3.0	16
274	Can response to locoregional therapy help predict longterm survival after liver transplantation for hepatocellular carcinoma? A systematic review. <i>Liver Transplantation</i> , 2017, 23, 375-385.	2.4	16
275	Circulating fibroblast activation protein activity and antigen levels correlate strongly when measured in liver disease and coronary heart disease. <i>PLoS ONE</i> , 2017, 12, e0178987.	2.5	16
276	Circulating Endothelial Progenitor Cells Present an Inflammatory Phenotype and Function in Patients With Alcoholic Liver Cirrhosis. <i>Frontiers in Physiology</i> , 2018, 9, 556.	2.8	16
277	Significance of serum and hepatic markers of hepatitis B viral infection in HBsAg-positive and HBsAg-negative chronic active hepatitis. <i>Hepatology</i> , 1985, 5, 50-53.	7.3	15
278	Selection of patients for liver transplantation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1993, 8, 185-194.	2.8	15
279	Liver transplantation for hepatitis C-associated cirrhosis in a single Australian centre: Referral patterns and transplant outcomes. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1997, 12, 453-459.	2.8	15
280	Withdrawal of immunosuppression in liver transplant recipients: Is this as good as it gets?. <i>Liver Transplantation</i> , 2002, 8, 408-410.	2.4	15
281	Combination adefovir/lamivudine prevents emergence of adefovir resistance in lamivudine-resistant hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 1500-1505.	2.8	15
282	De novo malignant disease after liver transplantation? Risk and surveillance strategies. <i>Liver Transplantation</i> , 2013, 19, S62-S67.	2.4	15
283	The CD8 T cell response during tolerance induction in liver transplantation. <i>Clinical and Translational Immunology</i> , 2016, 5, e102.	3.8	15
284	Relationship between hepatitis B virus DNA in blood and serological markers of hepatitis B infection. <i>Medical Journal of Australia</i> , 1986, 144, 351-355.	1.7	15
285	Dipeptidyl Peptidase Inhibition Enhances CD8 T Cell Recruitment and Activates Intrahepatic Inflammasome in a Murine Model of Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 5495.	3.7	15
286	Liver Graft Revascularization by Donor Portal Vein Arterialization Following "No Touch" Donor Hepatectomy. <i>HPB Surgery</i> , 1988, 1, 57-66.	2.2	14
287	An active liver transplant programme for hepatocellular carcinoma in cirrhotic patients: is it justified?. <i>Clinical Transplantation</i> , 1999, 13, 531-535.	1.6	14
288	Antioxidant levels in peripheral blood, disease activity and fibrotic stage in chronic hepatitis C. <i>Liver International</i> , 2005, 25, 518-526.	3.9	14

#	ARTICLE	IF	CITATIONS
289	Immune-mediated hepatitis drives low-level fusion between hepatocytes and adult bone marrow cells. <i>Journal of Hepatology</i> , 2006, 44, 334-341.	3.7	14
290	Liver Tolerance and the Manipulation of Immune Outcomes. <i>Inflammation and Allergy: Drug Targets</i> , 2008, 7, 6-18.	1.8	14
291	Increasing liver transplantation waiting list mortality: a report from the Australian National Liver Transplantation Unit, Sydney. <i>Internal Medicine Journal</i> , 2010, 40, 619-625.	0.8	14
292	Nature and outcomes of the increased incidence of colorectal malignancy after liver transplantation in Australasia. <i>Medical Journal of Australia</i> , 2013, 199, 610-612.	1.7	14
293	Distribution of interferon lambda $\epsilon$ 3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: Analysis from the PREDICT and CHARIOT studies. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 179-184.	2.8	14
294	Circulating CD147 predicts mortality in advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 459-466.	2.8	14
295	Aggressive nutrition intervention reduces ascites and frequency of paracentesis in malnourished patients with cirrhosis and ascites. <i>JGH Open</i> , 2017, 1, 92-97.	1.6	14
296	Excellent Contemporary Graft Survival for Adult Liver Retransplantation: An Australian and New Zealand Registry Analysis From 1986 to 2017. <i>Transplantation Direct</i> , 2019, 5, e472.	1.6	14
297	Platelet activating factor receptor acts to limit colitis-induced liver inflammation. <i>FASEB Journal</i> , 2020, 34, 7718-7732.	0.5	14
298	DANAZOL AND HEPATIC NEOPLASIA: A CASE REPORT. <i>Australian and New Zealand Journal of Medicine</i> , 1989, 19, 733-735.	0.5	13
299	Donor fatty (steatotic) liver allografts in orthotopic liver transplantation: a revisit. <i>Transplantation Proceedings</i> , 2000, 32, 2101-2102.	0.6	13
300	Alcohol and the Pancreas. <i>Alcoholism: Clinical and Experimental Research</i> , 2001, 25, 244S-250S.	2.4	13
301	Time course of upregulation of fibrogenic growth factors and cellular infiltration in a rodent model of chronic renal allograft rejection. <i>Transplant Immunology</i> , 2002, 10, 245-254.	1.2	13
302	Posttransplant Interleukin-4 Treatment Converts Rat Liver Allograft Tolerance to Rejection. <i>Transplantation</i> , 2005, 79, 1116-1120.	1.0	13
303	Assessment of adult patients with chronic liver failure for liver transplantation in 2015: who and when?. <i>Internal Medicine Journal</i> , 2016, 46, 404-412.	0.8	13
304	Analysis of human liver disease using a cluster of differentiation (CD) antibody microarray. <i>Liver International</i> , 2012, 32, 1527-1534.	3.9	12
305	Is there such a thing as protocol immunosuppression in liver transplantation?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 1-4.	3.0	12
306	Molecular profiling of postreperfusion milieu determines acute kidney injury after liver transplantation: A prospective study. <i>Liver Transplantation</i> , 2018, 24, 922-931.	2.4	12

#	ARTICLE	IF	CITATIONS
307	Prolonged Ex Vivo Normothermic Perfusion of a Split Liver. <i>Transplantation Direct</i> , 2021, 7, e763.	1.6	12
308	Dinucleotide repeat polymorphism at the D5S134 locus linked to the adenomatous polyposis coli (APC) gene. <i>Human Molecular Genetics</i> , 1992, 1, 655-655.	2.9	11
309	Dipeptidyl peptidase IV is down-regulated in rat hepatoma cells at the mRNA level. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1993, 8, 142-145.	2.8	11
310	Increased serum levels of dipeptidyl peptidase IV (CD26) in rats undergoing liver regeneration. <i>International Hepatology Communications</i> , 1995, 4, 165-174.	0.7	11
311	East meets West: Acute liver failure in the global village. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 467-469.	2.8	11
312	Simultaneous Vascularized Bone Marrow Transplantation to Promote Acceptance of Hind Limb Allografts and Its Effects on Central and Peripheral Chimerism. <i>Transplantation</i> , 2007, 83, 1273-1276.	1.0	11
313	Hepatocellular carcinoma development requires hepatic stem cells with altered transforming growth factor and interleukin-6 signaling. <i>Hepatology</i> , 2008, 47, 2134-2136.	7.3	11
314	New therapies against HCV: Expected risks and challenges associated with their use in the liver transplant setting. <i>Journal of Hepatology</i> , 2012, 57, 1361-1367.	3.7	11
315	Addressing the challenges of split liver transplantation through technical advances. A systematic review. <i>Transplantation Reviews</i> , 2021, 35, 100627.	2.9	11
316	Accumulation of Deleterious Passenger Mutations Is Associated with the Progression of Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0162586.	2.5	11
317	Hepatitis B virus precore mutant infection is associated with severe recurrent disease after liver transplantation. <i>Hepatology</i> , 1995, 21, 14-8.	7.3	11
318	Exon eight APC mutations account for a disproportionate number of familial adenomatous polyposis families. <i>Human Mutation</i> , 1994, 3, 12-18.	2.5	10
319	Relating Structure to Function in the Beta-Propeller Domain of Dipeptidyl Peptidase IV. , 2000, 477, 89-95.		10
320	Experimental limb transplantation, part III: Induction of tolerance in the rigorous strain combination of Brown Norway donor to Lewis recipient. <i>Transplantation Proceedings</i> , 2004, 36, 3276-3282.	0.6	10
321	Extra-Enzymatic Roles of DPIV and FAP in Cell Adhesion and Migration on Collagen and Fibronectin. , 2006, 575, 213-222.		10
322	Sinusoidal endothelium is essential for liver regeneration. <i>Hepatology</i> , 2011, 54, 731-733.	7.3	10
323	Trekking new ground: Overcoming medical and social impediments for extended criteria liver transplant recipients. <i>Liver Transplantation</i> , 2012, 18, S39-S46.	2.4	10
324	Terlipressin therapy for moderate to severe hyponatraemia in patients with liver failure. <i>Internal Medicine Journal</i> , 2013, 43, 240-246.	0.8	10

#	ARTICLE	IF	CITATIONS
325	Percutaneous Retroperitoneal Splenorenal Shunt for Symptomatic Portal Vein Thrombosis After Liver Transplantation. American Journal of Transplantation, 2015, 15, 2261-2264.	4.7	10
326	Molecular Analyses of Human and Rat Dipeptidyl Peptidase IV. Advances in Experimental Medicine and Biology, 1997, 421, 161-169.	1.6	10
327	Mutations in the hepatitis B virus precore/core gene and core promoter in patients with severe recurrent disease following liver transplantation. Hepatology, 1996, 24, 1371-1378.	7.3	10
328	Trp53 and Rb1 regulate autophagy and ligand-dependent Hedgehog signaling. Journal of Clinical Investigation, 2020, 130, 4006-4018.	8.2	10
329	THE ROLE OF HEPATITIS B VIRUS IN THE ETIOLOGY OF HEPATOCELLULAR CARCINOMA IN AUSTRALIA. Australian and New Zealand Journal of Medicine, 1983, 13, 605-607.	0.5	9
330	Risk estimation in familial adenomatous polyposis using DNA probes linked to the familial adenomatous polyposis gene.. Gut, 1992, 33, 530-534.	12.1	9
331	SUCCESSFUL REVERSAL OF PRIMARY GRAFT NONFUNCTION IN A LIVER TRANSPLANT PATIENT TREATED WITH PROSTAGLANDIN E <sub>1</sub> . ANZ Journal of Surgery, 1992, 62, 314-316.	0.7	9
332	Multiple endoscopies in a Sydney blood donor found positive for hepatitis B and C antibodies. Medical Journal of Australia, 1996, 164, 571-571.	1.7	9
333	Hepatitis C virus genotypes in a cohort of Australian blood donors and haemophiliac and liver transplant patients. Journal of Gastroenterology and Hepatology (Australia), 1997, 12, 182-187.	2.8	9
334	Microchimerism and transplant tolerance. Trends in Immunology, 1997, 18, 455-456.	7.5	9
335	LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA IN CIRRHOTIC PATIENTS. ANZ Journal of Surgery, 1999, 69, 798-801.	0.7	9
336	Molecular Approaches to the Side Effects of Immunosuppressive Drugs. Transplantation, 2004, 78, 1114-1115.	1.0	9
337	Intrahepatic interferon-stimulated gene responses: Can they predict treatment responses in chronic hepatitis C infection?. Hepatology, 2007, 46, 1326-1328.	7.3	9
338	The Murine Choline-Deficient, Ethionine-Supplemented (CDE) Diet Model of Chronic Liver Injury. Journal of Visualized Experiments, 2017, , .	0.3	9
339	How to select the appropriate "neoadjuvant therapy" for hepatocellular carcinoma. Expert Opinion on Pharmacotherapy, 2018, 19, 1167-1170.	1.8	9
340	DPP9: Comprehensive In Silico Analyses of Loss of Function Gene Variants and Associated Gene Expression Signatures in Human Hepatocellular Carcinoma. Cancers, 2021, 13, 1637.	3.7	9
341	Hepatitis B virus precore mutant infection is associated with severe recurrent disease after liver transplantation. Hepatology, 1995, 21, 14-18.	7.3	9
342	Tolerance to rat liver allografts. I. Differences between tolerance and rejection are more marked in the B cell compared with the T cell or cytokine response. Transplantation, 1994, 57, 1349-57.	1.0	9

#	ARTICLE	IF	CITATIONS
343	Recurrence of nonalcoholic steatohepatitis (NASH) post-liver transplantation. <i>Liver Transplantation</i> , 1997, 3, 683-683.	1.8	8
344	Nonspecificity of monoclonal antibody tordji-22 for the detection of hepatitis C virus in liver transplant recipients with cholestatic hepatitis. <i>Liver Transplantation</i> , 1999, 5, 40-45.	1.8	8
345	CASE REPORT: <i>Pinworm</i> Infection of the Liver: Unusual CT Appearance Leading to Hepatic Resection. <i>Digestive Diseases and Sciences</i> , 2004, 49, 466-468.	2.3	8
346	Combined donor leucocyte administration and immunosuppressive drug treatment for survival of rat heart allografts. <i>Transplant Immunology</i> , 2004, 13, 177-184.	1.2	8
347	Gene therapy in transplantation. <i>Transplantation Reviews</i> , 2009, 23, 159-170.	2.9	8
348	Advances in and the future of treatments for hepatitis C. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 633-647.	3.0	8
349	CD147 mediates intrahepatic leukocyte aggregation and determines the extent of liver injury. <i>PLoS ONE</i> , 2019, 14, e0215557.	2.5	8
350	Prevalence and outcomes of pancreatic cystic neoplasms in liver transplant recipients. <i>World Journal of Gastroenterology</i> , 2017, 23, 8526-8532.	3.3	8
351	Liver Endothelial Heg Regulates Vascular/Biliary Network Patterning and Metabolic Zonation Via Wnt Signaling. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 13, 1757-1783.	4.5	8
352	Tumour suppressor genes and colorectal neoplasia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1993, 8, 174-184.	2.8	7
353	Retransplantation for precore mutant-related chronic hepatitis B infection: Prolonged survival in a patient receiving sequential ganciclovir/famciclovir therapy. <i>Liver Transplantation</i> , 1996, 2, 472-474.	1.8	7
354	Atherosclerosis of the liver allograft. <i>Journal of Hepatology</i> , 1997, 27, 592-598.	3.7	7
355	Immunosuppression for HCV Following Liver Transplantation: Enough Is Just Enough. <i>Transplantation</i> , 2004, 78, 1413-1414.	1.0	7
356	Improvement in hepatopulmonary syndrome after methadone withdrawal: A case report with implications for disease mechanism. <i>Liver Transplantation</i> , 2010, 16, 870-873.	2.4	7
357	Cancer Risk After Organ Transplantation. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 663-663.	7.4	7
358	Expression of common gamma chain signalling cytokines and their receptors distinguishes rejection from tolerance in a rat organ transplant model. <i>Transplant Immunology</i> , 2012, 27, 89-94.	1.2	7
359	Operational tolerance in liver transplantation: Shall we predict or promote?. <i>Liver Transplantation</i> , 2013, 19, 933-936.	2.4	7
360	Hepatitis C Virus-Associated Cholestatic Hepatitis: We Cannot Seem to Agree on Diagnostic Criteria. <i>Liver Transplantation</i> , 2013, 19, 115-117.	2.4	7

#	ARTICLE	IF	CITATIONS
361	Analysis of Post-Liver Transplant Hepatitis C Virus Recurrence Using Serial Cluster of Differentiation Antibody Microarrays. <i>Transplantation</i> , 2015, 99, e120-e126.	1.0	7
362	Induction Phase of Spontaneous Liver Transplant Tolerance. <i>Frontiers in Immunology</i> , 2020, 11, 1908.	4.8	7
363	Cell surface phenotype of mononuclear cells infiltrating bile ducts during acute and chronic liver allograft rejection. <i>Transplantation Proceedings</i> , 1989, 21, 2201-2.	0.6	7
364	Clinicopathological approach to human liver allograft dysfunction. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1989, 4, 467-477.	2.8	6
365	Single-center experience of combined liver and kidney transplantation. <i>Transplantation Proceedings</i> , 1998, 30, 3256-3257.	0.6	6
366	Hepatitis C virus quasispecies: Misunderstood and mistreated?. <i>Liver Transplantation</i> , 2003, 9, 1048-1052.	2.4	6
367	Liver transplantation outcomes for Australian Aboriginal and Torres Strait Islanders. <i>Liver Transplantation</i> , 2014, 20, 798-806.	2.4	6
368	Longitudinal dose and type of immunosuppression in a national cohort of Australian liver, heart, and lung transplant recipients, 1984-2006. <i>Clinical Transplantation</i> , 2015, 29, 978-990.	1.6	6
369	Screening Emergency Admissions at Risk of Chronic Hepatitis C (SEARCH) to diagnose or re-diagnose™ infections is effective in Australia. <i>Journal of Viral Hepatitis</i> , 2021, 28, 121-128.	2.0	6
370	Patients with non-viral liver disease have a greater tumor burden and less curative treatment options when diagnosed with hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2017, 23, 2763.	3.3	6
371	Detection of serum hepatitis C virus RNA in HCV antibody-seropositive volunteer blood donors. <i>Hepatology</i> , 1993, 18, 485-90.	7.3	6
372	The Importance of Hepatitis B Infection in the Aetiology of Chronic Hepatitis: A Sydney Hospital Experience. <i>Australian and New Zealand Journal of Medicine</i> , 1982, 12, 19-21.	0.5	5
373	Antigen-specific suppression of anti-influenza antibody production in man. Possible role of a membrane-antigen complex. <i>European Journal of Immunology</i> , 1985, 15, 282-290.	2.9	5
374	Adult living donor liver transplantation: another Pandora's box?. <i>Medical Journal of Australia</i> , 2001, 175, 179-180.	1.7	5
375	Increased mononuclear cell activation and apoptosis early after human liver transplantation is associated with a reduced frequency of acute rejection. <i>Liver Transplantation</i> , 2004, 10, 397-403.	2.4	5
376	"I'll never touch it again, doctor!" harmful drinking after liver transplantation. <i>Hepatology</i> , 2007, 46, 1302-1304.	7.3	5
377	Heart allograft acceptance induced by anti-CD3 antibody in high-responder rats: Effect on foxp3 and cytokine expression and graft infiltration. <i>Transplant Immunology</i> , 2008, 19, 20-24.	1.2	5
378	Liver transplantation and hepatitis C: Will understanding the interleukin-28B polymorphisms improve outcomes?. <i>Liver Transplantation</i> , 2011, 17, 219-221.	2.4	5

#	ARTICLE	IF	CITATIONS
379	Effector T cell function rather than survival determines extent and duration of hepatitis in mice. <i>Journal of Hepatology</i> , 2016, 64, 1327-1338.	3.7	5
380	Interactions between primary sclerosing cholangitis and inflammatory bowel disease: implications in the adult liver transplant setting. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 949-960.	3.0	5
381	Have we significantly underestimated the capacity in the Australian health system to treat chronic hepatitis C infection in an interferon-free era?. <i>Internal Medicine Journal</i> , 2017, 47, 269-274.	0.8	5
382	Efficacy and safety profile of calcineurin inhibitor salvage therapy in autoimmune hepatitis. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 1309-1317.	1.5	5
383	DP8 and DP9 have Extra-Enzymatic Roles in Cell Adhesion, Migration and Apoptosis. , 2006, 575, 63-72.		5
384	Targeting Dipeptidyl Peptidase-4 (DPP-4) and Fibroblast Activation Protein (FAP) for Diabetes and Cancer Therapy. <i>RSC Drug Discovery Series</i> , 2011, , 118-144.	0.3	5
385	Deletion of kif3a in CK19 positive cells leads to primary cilia loss, biliary cell proliferation and cystic liver lesions in TAA-treated mice. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022, 1868, 166335.	3.8	5
386	The optimal immunosuppression management to prevent early rejection after liver transplantation: A systematic review of the literature and expert panel recommendations. <i>Clinical Transplantation</i> , 2022, 36, e14614.	1.6	5
387	Human liver allograft rejection: severity, prognosis, and response to treatment. <i>Transplantation Proceedings</i> , 1989, 21, 3792-3.	0.6	5
388	Validation of the <sc>aMAP</sc> score to predict hepatocellular carcinoma development in a cohort of alcoholâ€related cirrhosis patients. <i>Liver Cancer International</i> , 2022, 3, 99-104.	1.3	5
389	Is it safe to expand the indications for split liver transplantation in adults? A singleâ€centre analysis of 155 inâ€situ splits. <i>Clinical Transplantation</i> , 2022, , e14673.	1.6	5
390	ACUTE HEPATITIS B IN A METROPOLITAN POPULATION. <i>Medical Journal of Australia</i> , 1979, 2, 333-335.	1.7	4
391	Development of chronic hepatocerebral degeneration eight years after a distal splenorenal (Warren) shunt.. <i>Gut</i> , 1989, 30, 1419-1423.	12.1	4
392	DECISIONâ€MAKING IN 100 PATIENTS REFERRED TO THE AUSTRALIAN NATIONAL LIVER TRANSPLANTATION UNIT. <i>Australian and New Zealand Journal of Medicine</i> , 1989, 19, 132-137.	0.5	4
393	Liver transplantation utilizing pediatric cadaver donor livers. <i>Pediatric Transplantation</i> , 2005, 9, 47-51.	1.0	4
394	Locoregional therapies for hepatocellular carcinoma: Which patients are most likely to gain a survival advantage?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1299-1305.	2.8	4
395	Operational Tolerance in Organ Transplantation Versus Tissue Engineering: Into the Future. <i>Transplantation</i> , 2011, 92, e39.	1.0	4
396	Interleukin-28B rs12979860 C allele: Protective against advanced fibrosis in chronic hepatitis C genotype 1 infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1458-1462.	2.8	4

#	ARTICLE	IF	CITATIONS
397	Feasibility, acceptability and safety of a nurse led hepatitis B clinic based in the community. <i>Collegian</i> , 2015, 22, 233-240.	1.3	4
398	Immune regeneration in irradiated mice is not impaired by the absence of DPP9 enzymatic activity. <i>Scientific Reports</i> , 2019, 9, 7292.	3.3	4
399	Alcohol and the Pancreas. <i>Alcoholism: Clinical and Experimental Research</i> , 2001, 25, 244S-250S.	2.4	4
400	Pentoxifylline-induced drug rash with eosinophilia and systemic symptoms (DRESS) in a patient with caffeine intolerance. <i>Journal of Dermatological Case Reports</i> , 2013, 7, 77-81.	1.1	4
401	The molecular phenotypes of injury, steatohepatitis, and fibrosis in liver transplant biopsies in the INTERLIVER study. <i>American Journal of Transplantation</i> , 2022, 22, 909-926.	4.7	4
402	Hepatitis C infection in liver transplant patients. <i>Transplantation Proceedings</i> , 1992, 24, 2256.	0.6	4
403	Determinants of successful liver transplantation. <i>Transplantation Proceedings</i> , 1990, 22, 2144-5.	0.6	4
404	Expansion of Liver Transplantation Criteria for Hepatocellular Carcinoma from Milan to UCSF in Australia and New Zealand and Justification for Metroticket 2.0. <i>Cancers</i> , 2022, 14, 2777.	3.7	4
405	The liver contains distinct interconnected networks of <sup>CX3CR1</sup> macrophages, <sup>XCR1</sup> type 1 and <sup>CD301a</sup> type 2 conventional dendritic cells embedded within portal tracts. <i>Immunology and Cell Biology</i> , 2022, 100, 394-408.	2.3	4
406	Transvenous intrahepatic porto-systemic shunt (TIPSS): a new treatment for portal hypertension. <i>Australian and New Zealand Journal of Medicine</i> , 1994, 24, 133-135.	0.5	3
407	Severe hemolysis due to anti-D in a D-negative recipient of an orthotopic liver transplant. <i>Transfusion</i> , 1995, 35, 277-278.	1.6	3
408	Liver transplantation. <i>Australian and New Zealand Journal of Medicine</i> , 1997, 27, 371-378.	0.5	3
409	Current limitations to nucleoside analogue therapy for chronic hepatitis B virus infection in the liver transplant and non-transplant settings. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 227-229.	2.8	3
410	Hepatitis A, liver transplants and Indigenous communities. <i>Medical Journal of Australia</i> , 2000, 172, 6-7.	1.7	3
411	Pharmacotherapy of hepatocellular carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 2175-2185.	1.8	3
412	Donor Leukocytes Combine With Immunosuppressive Drug Therapy to Prolong Limb Allograft Survival. <i>Transplantation Proceedings</i> , 2005, 37, 2382-2384.	0.6	3
413	Snipping away at hepatitis C. <i>Hepatology</i> , 2010, 51, 703-705.	7.3	3
414	Prevention of post liver transplant HBV recurrence. <i>Hepatology International</i> , 2011, 5, 876-881.	4.2	3



#	ARTICLE	IF	CITATIONS
415	The long and the short of interferon-gamma-inducible protein 10 in hepatitis C virus infection. <i>Hepatology</i> , 2011, 54, 1875-1879.	7.3	3
416	“No one really knows why they are alive until they know what they'd die for” Lessons from the death of a living liver donor. <i>Liver Transplantation</i> , 2013, 19, 1169-1171.	2.4	3
417	Emerging role of endoscopic ultrasound-guided liver biopsy. <i>Gut</i> , 2020, , gutjnl-2020-322704.	12.1	3
418	Beware of Portal Vein Thrombosis After Laparoscopic Sleeve Gastrectomy in Liver Transplant Recipients. <i>Liver Transplantation</i> , 2021, 27, 1066-1067.	2.4	3
419	Liberal Use of Interposition Grafts for Arterial Reconstruction Is Safe and Effective in Adult Split Liver Transplantation. <i>Transplantation Direct</i> , 2021, 7, e735.	1.6	3
420	Prevalence and Impact of Fatty Liver Disease in Adult Deceased Liver Transplant Donors: Metabolic-Associated Fatty Liver Disease or Nonalcoholic Fatty Liver Disease?. <i>Liver Transplantation</i> , 2021, 27, 1498-1501.	2.4	3
421	Turning the Tide on Hepatitis C Virus-Related Liver Transplantation: The Return on Investment in Hepatitis C Virus Treatment in Australia and New Zealand. <i>Liver Transplantation</i> , 2022, 28, 236-246.	2.4	3
422	Prevalence and outcomes of <i>Clostridioides difficile</i> infection in liver transplant recipients. <i>Transplant Infectious Disease</i> , 2021, , e13758.	1.7	3
423	Identification of cytokine protein expression in human liver allograft rejection: methods development and expression of IL-1 beta, IL-6, IFN-gamma, and basic fibroblast growth factor. <i>Transplantation Proceedings</i> , 1992, 24, 2310-2.	0.6	3
424	Liver transplantation in chronic hepatitis B and C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15 Suppl, E172-4.	2.8	3
425	MELD-GRAIL and MELD-GRAIL-Na Are Not Superior to MELD or MELD-Na in Predicting Liver Transplant Waiting List Mortality at a Single-center Level. <i>Transplantation Direct</i> , 2022, 8, e1346.	1.6	3
426	Histopathological prediction of hepatitis B recurrence in liver allografts. <i>Pathology</i> , 1994, 26, 251-256.	0.6	2
427	Therapies for chronic hepatitis B: emerging roles for nucleoside analogues. <i>Australian and New Zealand Journal of Medicine</i> , 2000, 30, 556-558.	0.5	2
428	Postransplant hepatitis C virus quasispecies and cholestatic hepatitis. <i>Hepatology</i> , 2000, 32, 1182.	7.3	2
429	Treatment for cirrhosis-associated hyponatremia? Vaptans and aquaresis. <i>Hepatology</i> , 2007, 45, 1080-1081.	7.3	2
430	Use of Severely Steatotic Grafts in Liver Transplantation. <i>Annals of Surgery</i> , 2008, 248, 142-143.	4.2	2
431	Advances in viral hepatitis: 50 years of Australian gastroenterology. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, S132-5.	2.8	2
432	Early on-treatment viral load and baseline METAVIR score: improved prediction of sustained virological response in HCV genotype 1 patients. <i>Antiviral Therapy</i> , 2012, 17, 849-854.	1.0	2

#	ARTICLE	IF	CITATIONS
433	Early hepatocellular carcinoma – Is there such a thing as too early?. Journal of Hepatology, 2013, 58, 210-211.	3.7	2
434	Factors influencing donor and recipient decision making in adult-to-adult living donor liver transplantation: a survey of a non-transplant population. ANZ Journal of Surgery, 2017, 87, 177-181.	0.7	2
435	Does Frailty Correlate With Sarcopenia in Patients With Cirrhosis and Portal Hypertension?. Clinical Gastroenterology and Hepatology, 2017, 15, 156.	4.4	2
436	Adrenal Insufficiency in Cirrhosis: Don't Forget the Hypothalamus. Clinical Gastroenterology and Hepatology, 2021, 19, 1074.	4.4	2
437	An improved production and purification protocol for recombinant soluble human fibroblast activation protein alpha. Protein Expression and Purification, 2021, 181, 105833.	1.3	2
438	Standard Liver Function Tests and Their Limitations: Selectivity and sensitivity of individual serum bile acid levels in hepatic dysfunction. , 1997, , 178-203.		2
439	Fulminant hepatic failure post liver transplantation: clinical syndromes, correlations and outcomes. Transplant International, 1995, 8, 20-26.	1.6	2
440	Are split liver grafts a suitable option in high-risk liver transplant recipients?. Current Opinion in Organ Transplantation, 2021, 26, 675-680.	1.6	2
441	Regulation of antibody production by an antigen-specific EBV-transformed B-lymphoblastoid cell line: effect of high-dose antigen and antigen-pulsed T cells. Immunology, 1986, 58, 597-602.	4.4	2
442	Client resistance to hepatitis C treatment initiation in opioid agonist treatment clinics in Sydney, Australia: A qualitative study. Drug and Alcohol Review, 2022, 41, 706-714.	2.1	2
443	Improved survival after liver transplantation for primary biliary cirrhosis. Transplantation Proceedings, 1989, 21, 3788-9.	0.6	2
444	The Hidden Epidemic: The Prevalence and Impact of Concurrent Liver Diseases in Patients Undergoing Liver Transplantation in Australia and New Zealand. Transplantation Direct, 2022, 8, e1345.	1.6	2
445	Emerging Patterns of Hepatitis B Chronic Liver Disease in Australia. Australian and New Zealand Journal of Medicine, 1979, 9, 359-364.	0.5	1
446	PROGNOSTIC SIGNIFICANCE OF JAUNDICE AFTER RENAL TRANSPLANTATION. Australian and New Zealand Journal of Medicine, 1980, 10, 107-108.	0.5	1
447	Emerging therapies for hepatitis C virus (HCV) infection: the importance of HCV genotype. Australian and New Zealand Journal of Medicine, 2000, 30, 644-646.	0.5	1
448	Fifty years of gastroenterology in Australia. Journal of Gastroenterology and Hepatology (Australia), 2002, 14, 179-193.	2.8	1
449	Donor Leukocytes Combined With Delayed Immunosuppressive Drug Therapy Prolong Limb Allograft Survival. Transplantation Proceedings, 2005, 37, 4630-4633.	0.6	1
450	Adrenal insufficiency and liver disease – Re-search. Journal of Hepatology, 2008, 48, 1018.	3.7	1

#	ARTICLE	IF	CITATIONS
451	Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients. <i>Antiviral Therapy</i> , 2011, 16, 173-180.	1.0	1
452	Is the end of chronic hepatitis C virus infection in sight?. <i>Medical Journal of Australia</i> , 2012, 196, 614-614.	1.7	1
453	A case of portopulmonary hypertension spanning 18 years: successful use of bosentan for progressive disease after two liver transplantations. <i>Internal Medicine Journal</i> , 2012, 42, 600-601.	0.8	1
454	Testing your methylome: DNA methylation profiling of serum DNA of HCC patients. <i>Hepatology International</i> , 2013, 7, 785-787.	4.2	1
455	Impact of Having a Planned Additional Operation at Time of Liver Transplant on Graft and Patient Outcomes. <i>Journal of Clinical Medicine</i> , 2020, 9, 608.	2.4	1
456	Steroid-refractory T-cell mediated rejection after human metapneumovirus infection in a liver transplant recipient. <i>Pathology</i> , 2021, 53, 793-794.	0.6	1
457	IS THE T HELPER 1/T HELPER 2 PARADIGM OF ALLOGRAFT TOLERANCE DEAD OR HAS IT JUST BEEN TURNED UPSIDE DOWN?. <i>Transplantation</i> , 1999, 68, 1229-1230.	1.0	1
458	Hepatic transplantation for hepatitis B-associated liver disease. <i>Transplantation Proceedings</i> , 1992, 24, 194-5.	0.6	1
459	Characterization of the rat CD26 antigen. <i>Transplantation Proceedings</i> , 1990, 22, 2103-4.	0.6	1
460	CHRONIC HEPATITIS-AETIOLOGICAL CONSIDERATIONS. <i>Australian and New Zealand Journal of Medicine</i> , 1980, 10, 112-112.	0.5	0
461	<i>Journal of Gastroenterology and Hepatology</i> celebrates the first Asia-Pacific Digestive Week, Sydney, September 2001. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 17, 353-354.	2.8	0
462	Molecular Chimeras and Mutational Analysis in the Prolyl Oligopeptidase Gene Family. , 2003, 524, 49-55.		0
463	Liver transplantation for viral hepatitis. <i>British Journal of Hospital Medicine (London, England)</i> : 2005), 2005, 66, 08-12.	0.5	0
464	Current Management of HBV Pre and Post Liver Transplant. <i>Current Hepatitis Reports</i> , 2013, 12, 119-123.	0.3	0
465	Author reply. <i>Internal Medicine Journal</i> , 2013, 43, 607-607.	0.8	0
466	Professor Bruce Hall and the ABC. <i>Medical Journal of Australia</i> , 2014, 201, 322-322.	1.7	0
467	Could The Morning After liver transplant be immunologically interesting?. <i>Liver Transplantation</i> , 2015, 21, 1120-1122.	2.4	0
468	Our experts highlight the most important research articles across the spectrum of topics relevant to the field of hepatic oncology. <i>Hepatic Oncology</i> , 2015, 2, 13-14.	4.2	0

#	ARTICLE	IF	CITATIONS
469	Novel TOF-MS Means of Quantifying ApoAI Amyloid Protein Load After Combined Liver Kidney Transplantation. <i>Transplantation</i> , 2018, 102, e192-e193.	1.0	0
470	Sclerosing peritonitis post liver transplantation: a rare condition where surgery is an important treatment option. <i>ANZ Journal of Surgery</i> , 2018, 88, E424-E428.	0.7	0
471	Letter: elderly AIH patients-an important subgroup. Authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 615-615.	3.7	0
472	IDDF2019-ABS-0196â€¦Long term outcomes of utilizing donation after circulatory death grafts in liver transplantation â€œ an australian 12-year cohort study. , 2019, , .		0
473	IDDF2019-ABS-0220â€¦Long-term outcomes of utilizing extended criteria deceased donors in liver transplantation â€œ an australian 12-year cohort study. , 2019, , .		0
474	Quality of life indicators in hepatic encephalopathy following supplementation with branched chain amino acids and/or synbiotics: A postâ€œhoc analysis. <i>GastroHep</i> , 2021, 3, 50-57.	0.6	0
475	Immunology and Immunosuppression. , 2006, , 621-642.		0
476	Hepatitis B and Liver Transplantation. , 2009, , 145-167.		0
477	REPLY TO "CHIMERISM AND CLONAL EXHAUSTION". <i>Transplantation</i> , 1998, 66, 273.	1.0	0
478	Immunological Parameters Influencing Adaptive Immune Responses to the Hepatitis C Virus. , 2008, , 39-70.		0
479	Those Donor Leucocytes Again? This Time Itâ€™s VITT!. <i>Liver Transplantation</i> , 2022, 28, 164-166.	2.4	0
480	IDDF2020-ABS-0162â€¦Trends in hospitalised drug-induced liver injury from 2009 to 2019 â€œ the rise of non-prescription medications. , 2020, , .		0
481	The Delay of Arterialization After Initial Portal Reperfusion More Than Warm Ischemia Time May Determine Ischemic-type Biliary Injury. <i>Transplantation</i> , 2022, 106, e167-e168.	1.0	0
482	Liver allograft rejection: analysis of OKT3 rescue therapy. <i>Transplantation Proceedings</i> , 1992, 24, 2250-1.	0.6	0
483	Liver transplantation: a decade later. <i>Australian Family Physician</i> , 1995, 24, 365-9; 372-4.	0.5	0
484	Liver transplantation for alcoholic cirrhosis: outcomes and difficulties in patient selection. <i>Transplantation Proceedings</i> , 1995, 27, 2147.	0.6	0